Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis - Implications for serpin function

被引:40
作者
Gorlatova, NV
Elokdah, H
Fan, K
Crandall, DL
Lawrence, DA
机构
[1] Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA
[2] Wyeth Res, Collegeville, PA 19426 USA
[3] Wyeth Res, Princeton, NJ 08543 USA
关键词
D O I
10.1074/jbc.M208420200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mechanism for the conversion of plasminogen activator inhibitor-1 (PAI-1) from the active to the latent conformation is not well understood. Recently, a monoclonal antibody, 33138, was described that rapidly converts PAI-1 to the latent conformation (Verhamme, I., Kvassman, J. O., Day, D., Debrock, S., Vleugels, N., Declerck, P. J., and Shore, J. D. (1999) J. Biol. Chem. 274, 17511-17517). In an attempt to understand this interaction, and more broadly to understand the mechanism of the natural transition of PAI-1 to the latent conformation, we have used random mutagenesis to identify the 33B8 epitope in PAI-1. This site involves at least 8 amino acids scattered over more than two-thirds of the linear sequence that form a compact epitope on the PAI-1 three-dimensional structure. Surface plasmon resonance studies indicate a high affinity interaction between latent PAI-1 and 33B8 that is similar to100-fold higher than comparable binding to active PALL Structural modeling results together with surface plasmon resonance analysis of parental and site-directed PAI-1 mutants with disrupted 33B8 binding suggest the existence of a specific PAI-1 intermediate structure that is stabilized by 33B8 binding. These analyses strongly suggest that this intermediate form of PAI-1 has a partial insertion of the reactive center loop into beta-sheet A, and together, these data have significant implications for the general serpin mechanism of proteinase inhibition..
引用
收藏
页码:16329 / 16335
页数:7
相关论文
共 45 条
[1]   Helix D elongation and allosteric activation of antithrombin [J].
Belzar, KJ ;
Zhou, AW ;
Carrell, RW ;
Gettins, PGW ;
Huntington, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (10) :8551-8558
[2]   MOLECULAR EVOLUTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 FUNCTIONAL STABILITY [J].
BERKENPAS, MB ;
LAWRENCE, DA ;
GINSBURG, D .
EMBO JOURNAL, 1995, 14 (13) :2969-2977
[3]  
BJORK I, 1992, J BIOL CHEM, V267, P1976
[4]  
BJORK I, 1992, J BIOL CHEM, V267, P19047
[5]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE DEFICIENT MICE .2. EFFECTS ON HEMOSTASIS, THROMBOSIS, AND THROMBOLYSIS [J].
CARMELIET, P ;
STASSEN, JM ;
SCHOONJANS, L ;
REAM, B ;
VANDENOORD, JJ ;
DEMOL, M ;
MULLIGAN, RC ;
COLLEN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2756-2760
[6]  
CARRELL RW, 1992, CURR OPIN STRUC BIOL, V2, P438
[7]   Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms [J].
Debrock, S ;
Declerck, PJ .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1997, 1337 (02) :257-266
[8]  
Eitzman DT, 2000, BLOOD, V96, P4212
[9]   Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene [J].
Eitzman, DT ;
McCoy, RD ;
Zheng, XX ;
Fay, WP ;
Shen, TL ;
Ginsburg, D ;
Simon, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :232-237
[10]   TIME-RESOLVED POLARIZED FLUORESCENCE SPECTROSCOPY STUDIES OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - CONFORMATIONAL-CHANGES OF THE REACTIVE CENTER UPON INTERACTIONS WITH TARGET PROTEASES, VITRONECTIN AND HEPARIN [J].
FA, M ;
KAROLIN, J ;
ALESHKOV, S ;
STRANDBERG, L ;
JOHANSSON, LBA ;
NY, T .
BIOCHEMISTRY, 1995, 34 (42) :13833-13840